Weijie Cao

Weijie Cao

Auto-generated profile, based on publicly available information

Weijie Cao

Beijing Key Laboratory of Clinical Epidemiology, School of Public Health, Capital Medical University, Beijing, China

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 December 2019 in OMICS: A Journal of Integrative Biology
Verified
Journal Article
Open access
DLDi Liu
Di Liu
QLQihuan Li
Qihuan Li
XZXiaoyu Zhang
Xiaoyu Zhang
HWHao Wang
Hao Wang
WCWeijie Cao
Weijie Cao
YWYouxin Wang
Youxin Wang
Glycomics is a new subspecialty in omics systems sciences that offers significant promise for next-generation biomarkers on disease susceptibility, drug target discovery, and precision medicine. In this context, alternative immunoglobulin G (IgG) N -glycosylation has been reportedly implicated in several common chronic diseases, although systematic assessment is currently lacking in the literature. We conducted a systematic review of observational studies on IgG N -glycan variability and susceptibility to common chronic diseases. Observational studies reporting an association between diseases (such as colorectal cancer, dyslipidemia, ischemic stroke, rheumatoid arthritis, and systemic lupus erythematosus) and IgG N -glycans quantified by ultraperformance liquid chromatography were included. The glycans were categorized into 24 initial IgG glycan peaks (GPs). Notably, aging positively correlated with GP1, GP2, GP4–7, GP10, GP11, GP19, and GP24, while negatively correlated with GP8, GP12–15, GP17, GP18, GP20, GP21, and GP23 ( p < 0.05). The absolute value of significant correlation coefficients of age and IgG glycans ranged from 0.043 to 0.645. We found that the high levels of GP1–4, GP6, GP7, and GP24 and low levels of GP9, GP13–15, GP18, and GP23 could potentially increase the risk of disease. In conclusion, the present systematic review suggests that the field of glycomics, and GP1–4, GP6, GP7, GP9, GP13–15, GP18, GP23, and GP24 in particular, holds promise for further candidate biomarker research on susceptibility to common chronic diseases.